NCT01766518

The Study to Evaluate Efficacy and Safety of MY-REPT Capsule in Primary, Liver Transplantation Recipients (MYLT1)

Open Label, Multicenter, Non-comparative Study to Evaluate the Efficacy and Safety of MY-REPT Capsule in Primary, Liver Transplantation Recipients.

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 19 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Efficacy and safety of MY-REPT capsule in primary, liver transplantation recipients

Detailed description

Open label, Multicenter, Non-comparative Study to evaluate the efficacy and safety of MY-REPT capsule in primary, liver transplantation

Conditions

• Evidence of Liver Transplantation

Interventions

Type	Name	Description
DRUG	Mycophenolate mofetil	MY-REPT capsule 500\~1500mg/day, per oral, capsules twice a day with Tacrolimus, Corticosteroids, Basiliximab post liver transplantation

Timeline

• Start date: 2009-11-01
• Primary completion: 2014-04-01
• Completion: 2014-05-01
• First posted: 2013-01-11
• Last updated: 2013-11-07

Locations

3 sites across 1 country: South Korea